Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned future fundraising through debt or equity. Mukesh Surana mentioned CAPEX guidance of Rs. 600 crores for FY '26, which includes investments in Granules Life Science, oncology, peptides, and the Senn Chemicals acquisition. The Senn Chemicals acquisition involved an enterprise value of Rs. 450 crores, financed through a combination of equity and debt. There is no direct indication of new fundraising; rather, investments appear to be funded through existing resources, including prior raised capital. The company is focusing on expans

Any current/future capex/capital investment/strategic investment?

Granules India spent Rs. 313 crores on Granules Life Sciences (GLS) in FY '25, with additional CAPEX planned in FY '26. CAPEX for FY '26 is guided at Rs. 600 crores, covering GLS expansion, oncology, and peptide investments. CZRO project CAPEX is minimal in FY '25, focusing on land acquisition and pilot facilities; expansion to proceed cautiously. Peptide R&D facility is being set up in Hyderabad, followed by peptide manufacturing. Senn Chemicals acquisition involves ongoing CAPEX for enhancing CDMO capabilities and GLP-1 product development; the investment is over and above the Rs. 60

Future growth expectations in sales/revenue/volumes?

Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products. Expansion of the Europe and Rest of World (ROW) business, focusing on finished dosages and increasing API and PFI business. Increased focus on formulation segment, aiming for around 25% of revenues from API with emphasis on in-house consumption. Genome Valley formulation site to play a significant role in revenue growth, especially as Gagillapur facility normalizes post-remediation. Strategic shift towards high-margin finished dosage products leading

Future growth expectations in earnings/operating earnings/profits/EPS?

Oncology portfolio expected to start generating revenue from FY '28 onwards, with multiple filings planned quarterly. Granules Life Sciences (GLS) expansion to achieve ~40% capacity utilization in FY '25 and close to 90%+ by FY '26 end. Focus on vertical integration, especially in API, to drive differentiation and margin improvement. GLS and peptide facilities are priority CAPEX areas, with ₹600 crores planned for FY '26 including Senn Chemicals investment. Transition toward higher-margin formulations and global markets like Europe and ROW to diversify revenue beyond North America. Despite ong

Current/ Expected Orderbook/ Pending Orders?

Granules India has a strong and diverse product portfolio with a total of 127 dossiers filed across various regions. They have 85 ANDAs in the US (16 pending approval), 18 dossiers in Europe (10 pending approval), and 24 in other regions including Canada (8 pending approval). In Q4 FY '25, they filed 3 US ANDAs and 6 European dossiers, including a first-to-file product from the GPI facility. The oncology pipeline includes around 10 products under development with filings already initiated in US and Europe. The ADHD portfolio has about 10 products in the pipeline, including day 1 launches, day

IN US

Sale is live|00:00:00left today

Granules India LtdQ1 FY25Pharmaceuticals & Biotechnology

Granules India Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹776P/E: 30.3Market Cap: ₹18.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline including first-to-launch and Para IV products.
→Expansion of the Europe and Rest of World (ROW) business, focusing on finished dosages and increasing API and PFI business.
→Increased focus on formulation segment, aiming for around 25% of revenues from API with emphasis on in-house consumption.
→Genome Valley formulation site to play a significant role in revenue growth, especially as Gagillapur facility normalizes post-remediation.
→Strategic shift towards high-margin finished dosage products leading to improved gross margins.
→Granules Life Sciences capacity utilization projected to increase from about 40% in current year to over 90% next year, driving revenue growth.
→Planned continuous R&D and new product launches to sustain medium to long-term growth.
→CAPEX to support expansion in GLS and oncology/peptide facilities for future growth.
→Slowdown at Gagillapur expected for 1-2 quarters but full-year revenue to improve over last year.

Margin guidance

Category 3

→Oncology portfolio expected to start generating revenue from FY '28 onwards, with multiple filings planned quarterly.
→Granules Life Sciences (GLS) expansion to achieve ~40% capacity utilization in FY '25 and close to 90%+ by FY '26 end.
→Focus on vertical integration, especially in API, to drive differentiation and margin improvement.
→GLS and peptide facilities are priority CAPEX areas, with ₹600 crores planned for FY '26 including Senn Chemicals investment.
→Transition toward higher-margin formulations and global markets like Europe and ROW to diversify revenue beyond North America.
→Despite ongoing Gagillapur remediation slowing operations, overall improvement over last year is expected.
→EBITDA grew 10% in FY '25 and is expected to improve further with better product mix and operational efficiencies.
→R&D investment continues to support new product development and differentiated portfolios.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not explicitly mention any current or planned future fundraising through debt or equity.
→Mukesh Surana mentioned CAPEX guidance of Rs. 600 crores for FY '26, which includes investments in Granules Life Science, oncology, peptides, and the Senn Chemicals acquisition.
→The Senn Chemicals acquisition involved an enterprise value of Rs. 450 crores, financed through a combination of equity and debt.
→There is no direct indication of new fundraising; rather, investments appear to be funded through existing resources, including prior raised capital.
→The company is focusing on expansion and CAPEX but has not provided updates on fresh debt or equity raising plans during this call.

Order book

→Granules India has a strong and diverse product portfolio with a total of 127 dossiers filed across various regions.
→They have 85 ANDAs in the US (16 pending approval), 18 dossiers in Europe (10 pending approval), and 24 in other regions including Canada (8 pending approval).
→In Q4 FY '25, they filed 3 US ANDAs and 6 European dossiers, including a first-to-file product from the GPI facility.
→The oncology pipeline includes around 10 products under development with filings already initiated in US and Europe.
→The ADHD portfolio has about 10 products in the pipeline, including day 1 launches, day 181 opportunities, and some first-to-file.
→The company expects the oncology portfolio to start yielding revenue from FY '28 onwards.
→The focus remains on vertical integration and in-house API manufacturing to support these filings and commercial launches.

Capex plans

Yes

→Granules India spent Rs. 313 crores on Granules Life Sciences (GLS) in FY '25, with additional CAPEX planned in FY '26.
→CAPEX for FY '26 is guided at Rs. 600 crores, covering GLS expansion, oncology, and peptide investments.
→CZRO project CAPEX is minimal in FY '25, focusing on land acquisition and pilot facilities; expansion to proceed cautiously.
→Peptide R&D facility is being set up in Hyderabad, followed by peptide manufacturing.
→Senn Chemicals acquisition involves ongoing CAPEX for enhancing CDMO capabilities and GLP-1 product development; the investment is over and above the Rs. 600 crore CAPEX for Granules.
→Total CAPEX including Senn Chemicals is expected to be around Rs. 1,100 crores (Rs. 600 crores + Rs. 450 crores enterprise value for Senn).
→GLS Phase-II commercial dispatches started; full 7.5 billion dosage capacity commercialization expected by Q2 FY '26.
→Peptide and oncology facilities are strategic priorities for future growth.

How does Granules India Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Granules India Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Granules India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio